At a glance
ClinicalIndex Comparison RecordN/ACompleted· 101 enrolled
Drug / intervention
histamine-2 receptor antagonist group +1 moredrug
Likely dose
histamine-2 receptor antagonist group 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial
In Brief
A clinical study evaluating histamine-2 receptor antagonist group and proton pump inhibitor group for Peptic Ulcer. Completed, enrolled 101 participants across 1 site.
Detailed Summary
Whether pantoprazole versus famotidine for the prevention of recurrent peptic ulcers in thienopyridine users remains unclear.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeptic Ulcer
CountriesTaiwan
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedSep 2015
Primary CompletionJul 2018
TodayJul 2026
First PostedSep 16, 2015
Enrollment StartJul 1, 2012
Primary CompletionJul 1, 2018
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 10.8 years ago
Interventions
histamine-2 receptor antagonist groupdrug
famotidine tab 40 mg qd for 6 months.
proton pump inhibitor groupdrug
pantoprazole tab 40 mg qd for 6 months.